Introduction {#sec1}
============

In this unique, historic period affected by a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, radiation therapy (RT) treatments cannot be delayed or suspended. Several consensus papers regarding the delivery of RT in different settings and cancer histologies have been published on the topic of limiting the spread of coronavirus disease 2019 (COVID-19) infection in radiation oncology departments, suggesting that patients should be treated using hypofractionated schemes and that radical treatments should be prioritized over adjuvant treatments.[@bib1]^,^[@bib2] The development of image guided radiation therapy during the last 2 decades has allowed radiation oncologists to fix any set-up error, to verify the target position, and even to perform adaptive RT, but it can also be useful to assess healthy lung tissue.[@bib3]

Case Description {#sec2}
================

We report the case of a 73-year-old woman with recently diagnosed extensive-stage small cell lung cancer, with metastatic liver and bone lesions. In the oncological anamnesis she had right breast cancer 15 years before, treated with surgery and postoperative RT, plus 5 years of hormone therapy, with negative follow-up.

She was admitted to our hospital on March 21, 2020, to start systemic treatment and was then referred for RT for two pathologic vertebral lesions with an initial spread to the spinal canal. A SARS-CoV-2 test was performed at the hospital admission and was negative.

On March 23 the patient was sent to the radiation oncology department for computed tomography (CT) simulation to treat the bone lytic lesions affecting the bodies of the 6th and 11th thoracic vertebrae. She did not have neurologic symptoms, so she first started chemotherapy (carboplatin AUC5 + etoposide q3w) from March 23 to 25. On the 26th she underwent RT on T6 and T11 with single fractions of 8 Gy each. The treatment was delivered on a TrueBeam STX (v2.5), with a multiple field static intensity modulated radiation therapy technique. Before treatment a cone beam CT (CBCT) was performed to check the setup of the patient. The acquisition protocol used for CBCT imaging was half fan and full rotation (125 kV and 270 mAs), half bow-tie filter applied, and no iterative reconstruction applied.

The next day the radiation oncologist performed the offline review of treatment setup comparing the CBCT acquired in the RT treatment room with the CT simulation. Some suspected lung areas of ground glass opacities (GGOs) were clearly visible in the CBCT without any counterpart in the previous scan ([Fig 1](#fig1){ref-type="fig"}); after discussion with the radiologist, it was decided to perform a new chest CT scan that confirmed the previously suspected GGOs ([Fig 2](#fig2){ref-type="fig"}). In fact, the examination revealed multiple bilateral areas of subpleural GGOs, which are the primary findings on CT scan in the early phases of COVID-19 lung infection, and also pleural effusions, a finding that may occur as a complication of COVID-19. The patient then urgently repeated the SARS-CoV-2 test, which was positive and confirmed the infection. On March 28 she was transferred to the infective disease COVID-19 department, where she is still hospitalized as we write this article.Figure 1Computed tomography (CT) simulation scan on March 23, 2020, (A1-A2) versus cone beam CT (CBCT) (B1-B2) acquired March 26, 2020, as registered before treatment delivery. Red arrows highlight the development of ground glass opacities (GGOs).Figure 2Chest computed tomography (CT) scan (C1-C2) acquired on March 27, 2020. Red arrows confirm the presence of ground glass opacities (GGOs) correlated with the initial onset of coronavirus disease 2019 (COVID-19) pneumonitis.

Discussion {#sec3}
==========

At the earliest stage of COVID-19 disease, a noncontrast chest CT scan has high sensitivity for the detection of GGOs in the SARS-CoV-2 infection,[@bib4] and this could justify its use in the early imaging in the acute phase in selected cases. This is relevant because early detection could improve patient outcome for COVID-related pneumonia, characterized by a release of proinflammatory cytokines followed by activation and production of active mediators of lung inflammation, fever, and fibrosis.[@bib5]

During this pandemic COVID-19 infection, the role of hypofractionated RT has grown because of its advantages in reducing the spread of the disease by limiting patient access.[@bib1] In this setting, the routine use of CBCT allows radiation oncologists to perform customized treatments with higher dose per fraction.[@bib2] In an article soon to be published, the authors found that CBCT has the potential to detect early COVID-19 lung disease.[@bib6]

In this case report the patient first had a negative SARS-CoV-2 test and took a second one after the appearance of GGOs on the CT scan, the day after RT, owing to findings on CBCT.

Conclusions {#sec4}
===========

In conclusion, daily CBCT can be effective for early detection of COVID-19 lung disease in asymptomatic or mildly symptomatic patients, helping to prevent the diffusion of this contagious disease to the care providers and other patients in the radiation oncology department.
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